Conditions: Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 103
Healthy volunteers: no

Brief summary:
The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and CA-125 tests will be done before the first dose and then after every other treatment.

Detailed description:

Arms:
arm 1: LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.

Interventions: intervention 1: LY573636-sodium
Intervention descriptions: intervention 1: LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.

Protocol document: